Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eli Global
Indianapolis, Indiana, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Eli Lilly is the most valuable pharmaceutical company worldwide and reached a $1 trillion market capitalization in November 2025, the first healthcare company globally to achieve this milestone. The company's primary revenue driver is tirzepatide (Mounjaro and Zepbound) accounting for 37% of 2024 revenues. Recent clinical successes include FDA approval of Kisunla (donanemab-azbt) for early Alzheimer's disease in July 2024, expansion of Zepbound to obstructive sleep apnea in December 2024, and Omvoh approval extension to Crohn's disease in January 2025.
- Therapeutic areas
- EndocrinologyNeurologyDermatologyInfectious DiseasesPulmonologyGastroenterologyOncology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateRadiopharmaceuticalGene therapyPeptides
- Industry
- Pharma
02
Partnerships
Amylin PharmaceuticalsHanmi PharmaceuticalInnovent BiologicsPfizerShionogiAbCelleraDisarm TherapeuticsProtomer TechnologiesTRexBioAmazonGinkgo BioworksOwkin
Beyond the preview
Go deeper on Eli Global.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eli Global.